Alnylam uses RNA interference to 'silence' disease-causing genes, creating medicines for rare genetic, heart, liver, and eye conditions.
Revenue hit USD 3.71B in 2025 with gross margins near 82%, and the company turned profitable with net income of USD 0.31B. Money comes from selling its approved treatments (ONPATTRO, GIVLAARI, OXLUMO) plus partner payments from Regeneron and Sanofi.
RNAi platform has deep patent protection and 20+ years of expertise; competitors like Ionis, Dicerna, and Arrowhead would need to match both science and manufacturing. Still, RNAi isn't exclusive—Ionis' antisense and other platforms compete, and partnerships g
Hold (sector percentile 65) — value C+, growth A, profitability A+, momentum F, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
At least two independent sources confirm analyst initiations with a $318 price target, indicating increased institutional attention
Q2 revenue $1.172B but guidance cut triggers multiple securities investigations
SBS and Bragar Eagel & Squire launch probes; the latter cites July 30 $200M TTR sales reduction
Broker upgrade contrasts with recent guidance cut
Q2 miss and guidance cut on Amvuttra 2L demand normalization trigger stock plunge and securities fraud probes.
Institutional holding change reflects long-term fund allocation, but single source and quarterly disclosure limit impact.
Fifth Third Bancorp raised stake by 7433.9%, Andra AP fonden by 78.6%, showing institutional interest
Seeking Alpha initiates with Buy, calling pullback overreaction; AMVUTTRA holds near-term commercial monopoly in TTR silencing
Company to report Q2 2026 results and host webcast conference call
Rival Wainua/eplontersen missed primary endpoint; market sees as positive for ALNY
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
